UCB (OTCMKTS:UCBJY) Sees Unusually-High Trading Volume – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJY) saw unusually-strong trading volume on Friday . Approximately 76,781 shares traded hands during trading, an increase of 103% from the previous session’s volume of 37,756 shares.The stock last traded at $129.1150 and had previously closed at $129.33.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on UCBJY. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday. Finally, Zacks Research raised UCB from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, UCB presently has a consensus rating of “Buy”.

UCB Stock Performance

The firm’s 50-day moving average is $142.52 and its 200-day moving average is $146.82. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.